Therapeutic Potential of Prostaglandins in Dermatology: Focus on Vitiligo

  • 作者: Djahaia E.Y.1, Kruchkova K.Y.2, Kayumova L.N.3, Smirnov K.V.4, Lomonosov K.M.4
  • 隶属关系:
    1. Федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский Университет)
    2. I.M. Sechenov First Moscow State Medical University (Sechenov University)
    3. The First Sechenov Moscow State Medical University (Sechenov University)
    4. Sechenov First Moscow State Medical University (Sechenov University)
  • 栏目: DERMATOLOGY
  • ##submission.dateSubmitted##: 31.03.2025
  • ##submission.dateAccepted##: 17.08.2025
  • ##submission.datePublished##: 22.09.2025
  • URL: https://rjsvd.com/1560-9588/article/view/677914
  • DOI: https://doi.org/10.17816/dv677914
  • ID: 677914


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

This article is devoted to the analysis of the therapeutic potential of prostaglandins (PGs) in dermatology, with a particular focus on their application in vitiligo. Due to their unique properties, prostaglandins exert a complex effect: on one hand, they activate melanocytes and stimulate melanogenesis; on the other, they modulate the immune response by suppressing autoimmune reactions. The article provides a detailed examination of the mechanisms of PG action, including their role in inflammation regulation and interaction with skin receptors. The advantages of using prostaglandins in combination therapies for vitiligo are discussed, particularly in conjunction with phototherapy, microneedling, and laser-based methods. Evidence is presented demonstrating the high efficacy of prostaglandins in the treatment of vitiligo, especially in resistant forms of the disease. The paper emphasizes that the use of PGs may significantly enhance the effectiveness of vitiligo treatment by increasing repigmentation stability and ensuring more consistent clinical outcomes. The authors also highlight the need for further research to optimize dosages, treatment regimens, and duration of prostaglandin therapy. The literature search methodology included a systematic review of scientific publications from 1987 to 2025 in databases such as PubMed, Scopus, Web of Science, and eLIBRARY.ru.

全文:

受限制的访问

作者简介

Elizaveta Djahaia

Федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский Университет)

编辑信件的主要联系方式.
Email: elizaveta_djahaia@mail.ru
ORCID iD: 0009-0002-3741-6619
SPIN 代码: 8308-7621

Врач-аспирант на кафедре кожных и венерических болезней В.А. Рахманова

俄罗斯联邦

Kira Kruchkova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: kira.kruchkova@mail.ru
ORCID iD: 0000-0002-1172-9695
SPIN 代码: 4743-6244
俄罗斯联邦, Moscow

Lyailya Kayumova

The First Sechenov Moscow State Medical University (Sechenov University)

Email: avestohka2005@inbox.ru
ORCID iD: 0000-0003-0301-737X
SPIN 代码: 4391-9553

MD, Cand. Sci. (Medicine), Assistant Professor

俄罗斯联邦, Moscow

Konstantin Smirnov

Sechenov First Moscow State Medical University (Sechenov University)

Email: puva3@mail.ru
ORCID iD: 0000-0001-7660-7958
SPIN 代码: 2054-1086

MD, Cand. Sci. (Med.)

俄罗斯联邦, Moscow

Konstantin Lomonosov

Sechenov First Moscow State Medical University (Sechenov University)

Email: lamclinic@yandex.ru
ORCID iD: 0000-0002-4580-6193
SPIN 代码: 4784-9730

MD, Dr. Sci. (Med.), Professor

俄罗斯联邦, Moscow

参考

  1. Yanes DA, Mosser-Goldfarb JL. Emerging therapies for atopic dermatitis: The prostaglandin/leukotriene pathway. J Am Acad Dermatol. 2018;78(3 Suppl 1):S71-S75. https://pubmed.ncbi.nlm.nih.gov/29248523/
  2. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP. Prostaglandins as modulators of immunity. Trends Immunol. 2002;23(3):144-150. https://pubmed.ncbi.nlm.nih.gov/11864843/
  3. Oyesola OO, Tait Wojno ED. Prostaglandin regulation of type 2 inflammation: From basic biology to therapeutic interventions. Eur J Immunol. 2021;51(10):2399-2416. https://pubmed.ncbi.nlm.nih.gov/34396535/
  4. Ricciotti E, Fitzgerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011;31(5):986-1000. https://pubmed.ncbi.nlm.nih.gov/21508345/
  5. Cheng H, Huang H, Guo Z, Chang Y, Li Z. Role of prostaglandin E2 in tissue repair and regeneration. Theranostics. 2021;11(18):8836. https://pmc.ncbi.nlm.nih.gov/articles/PMC8419039/
  6. Yasukawa K, Okuno T, Yokomizo T. Eicosanoids in Skin Wound Healing. Int J Mol Sci 2020, Vol 21, Page 8435. 2020;21(22):8435. https://www.mdpi.com/1422-0067/21/22/8435/htm
  7. Wautier JL, Wautier MP. Pro- and Anti-Inflammatory Prostaglandins and Cytokines in Humans: A Mini Review. Int J Mol Sci 2023, Vol 24, Page 9647. 2023;24(11):9647. https://www.mdpi.com/1422-0067/24/11/9647/htm
  8. Bull HA, Dowd PM. Prostaglandins, Interleukins, and Cutaneous Inflammation. Immunomethods. 1993;2(3):219-226.
  9. Calabrese L, Fiocco Z, Satoh TK, Peris K, French LE. Therapeutic potential of targeting interleukin‐1 family cytokines in chronic inflammatory skin diseases. Br J Dermatol. 2022;186(6):925-941. https://dx.doi.org/10.1111/bjd.20975
  10. Honda T, Kabashima K. Prostanoids in allergy. Allergol Int. 2015;64(1):11-16.
  11. Hensby CN, Shroot B, Schaefer H, Juhlin L, Ortonne JP. Prostaglandins in human skin disease. Br J Dermatol. 1983;109 Suppl 25:22-25. https://pubmed.ncbi.nlm.nih.gov/6574787/
  12. Alestas T, Ganceviciene R, Fimmel S, Müller-Decker K, Zouboulis CC. Enzymes involved in the biosynthesis of leukotriene B4 and prostaglandin E2 are active in sebaceous glands. J Mol Med (Berl). 2006;84(1):75-87. https://pubmed.ncbi.nlm.nih.gov/16388388/
  13. Altman K, Chang C. Pathogenic intracellular and autoimmune mechanisms in urticaria and angioedema. Clin Rev Allergy Immunol. 2013;45(1):47-62. https://pubmed.ncbi.nlm.nih.gov/22674016/
  14. Greaves MW, McDonald-Gibson W. Itch: Role of Prostaglandins. Br Med J. 1973;3(5881):608. https://pmc.ncbi.nlm.nih.gov/articles/PMC1586899/
  15. Lovell CR, Burton PA, Duncan EHL, Burton JL. Prostaglandins and pruritus. Br J Dermatol. 1976;94(3):273-275. https://pubmed.ncbi.nlm.nih.gov/1252358/
  16. Nagai H. Prostaglandin as a Target Molecule for Pharmacotherapy of Allergic Inflammatory Diseases. Allergol Int. 2008;57(3):187-196.
  17. Shiraishi N, Nomura T, Tanizaki H, et al. Prostaglandin E2-EP3 Axis in Fine-Tuning Excessive Skin Inflammation by Restricting Dendritic Cell Functions. PLoS One. 2013;8(7):e69599. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0069599
  18. Angeli V, Staumont D, Charbonnier A-S, et al. Activation of the D Prostanoid Receptor 1 Regulates Immune and Skin Allergic Responses. J Immunol. 2004;172(6):3822-3829. https://dx.doi.org/10.4049/jimmunol.172.6.3822
  19. Sarashina H, Tsubosaka Y, Omori K, et al. Opposing immunomodulatory roles of prostaglandin D2 during the progression of skin inflammation. J Immunol. 2014;192(1):459-465. https://pubmed.ncbi.nlm.nih.gov/24298012/
  20. Cordeiro, M.F., et al. How latanoprost changed glaucoma management // Acta Ophthalmologica, 2023. Vol. 102, № 1. P. e140–e155.
  21. Bakker R, Pierce S, Myers D. The role of prostaglandins E1 and E2, dinoprostone, and misoprostol in cervical ripening and the induction of labor: a mechanistic approach. Arch Gynecol Obstet. 2017;296(2):167-179. https://pubmed.ncbi.nlm.nih.gov/28585102/
  22. Chiba T, Kashiwagi K, Kogure S, et al. Iridial pigmentation induced by latanoprost ophthalmic solution in Japanese glaucoma patients. J Glaucoma. 2001;10(5):406-410. https://pubmed.ncbi.nlm.nih.gov/11711839/
  23. Alexander CL, Miller SJ, Abel SR. Prostaglandin analog treatment of glaucoma and ocular hypertension. Ann Pharmacother. 2002;36(3):504-511. https://pubmed.ncbi.nlm.nih.gov/11895065/
  24. Inoue K, Shiokawa M, Higa R, et al. Adverse periocular reactions to five types of prostaglandin analogs. Eye (Lond). 2012;26(11):1465-1472. https://pubmed.ncbi.nlm.nih.gov/23037910/
  25. Carruthers J, Beer K, Carruthers A, et al. Bimatoprost 0.03% for the Treatment of Eyebrow Hypotrichosis. Dermatol Surg. 2016;42(5):608-617. https://pubmed.ncbi.nlm.nih.gov/27124878/
  26. Beer KR, Julius H, Dunn M, Wilson F. Treatment of eyebrow hypotrichosis using bimatoprost: a randomized, double-blind, vehicle-controlled pilot study. Dermatol Surg. 2013;39(7):1079-1087. https://pubmed.ncbi.nlm.nih.gov/23617229/
  27. Yoelin SG, Fagien S, Cox SE, et al. A retrospective review and observational study of outcomes and safety of bimatoprost ophthalmic solution 0.03% for treating eyelash hypotrichosis. Dermatol Surg. 2014;40(10):1118-1124. https://pubmed.ncbi.nlm.nih.gov/25229783/
  28. Blume-Peytavi U, Lönnfors S, Hillmann K, Garcia Bartels N. A randomized double-blind placebo-controlled pilot study to assess the efficacy of a 24-week topical treatment by latanoprost 0.1% on hair growth and pigmentation in healthy volunteers with androgenetic alopecia. J Am Acad Dermatol. 2012;66(5):794-800. https://pubmed.ncbi.nlm.nih.gov/21875758/
  29. Renert-Yuval Y, Guttman-Yassky E. The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm. Adv Ther. 2017;34(7):1594-1609. https://pubmed.ncbi.nlm.nih.gov/28646393/
  30. Levy LL, Emer JJ. Female pattern alopecia: current perspectives. Int J Womens Health. 2013;5(1):541-556. https://pubmed.ncbi.nlm.nih.gov/24039457/
  31. Barrón-Hernández YL, Tosti A. Bimatoprost for the treatment of eyelash, eyebrow and scalp alopecia. Expert Opin Investig Drugs. 2017;26(4):515-522. https://pubmed.ncbi.nlm.nih.gov/28264599/
  32. Barton VR, Toussi A, Awasthi S, Kiuru M. Treatment of pediatric alopecia areata: A systematic review. J Am Acad Dermatol. 2021;86(6):1318. https://pmc.ncbi.nlm.nih.gov/articles/PMC8556406/
  33. Nashan D, Nieschlag E. Male Androgenetic Alopecia. Androl Male Reprod Heal Dysfunction, Fourth Ed. Published online January 25, 2023:491-499. https://www.ncbi.nlm.nih.gov/books/NBK278957/
  34. Eriksson L, Lindström B, Ekenberg L. Patients’ experiences of telerehabilitation at home after shoulder joint replacement. J Telemed Telecare. 2011;17(1):25-30. https://pubmed.ncbi.nlm.nih.gov/21075802/
  35. De Caridi G, Massara M, Stilo F, et al. Effectiveness of prostaglandin E1 in patients with mixed arterial and venous ulcers of the lower limbs. Int Wound J. 2014;13(5):625. https://pmc.ncbi.nlm.nih.gov/articles/PMC7950138/
  36. Massaki ABMN, Fabi SG, Fitzpatrick R. Repigmentation of hypopigmented scars using an erbium-doped 1,550-nm fractionated laser and topical bimatoprost. Dermatologic Surg. 2012;38(7 PART 1):995-1001.
  37. Matejka M, Nell A, Kment G, et al. Local benefit of prostaglandin E2 in radiochemotherapy-induced oral mucositis. Br J Oral Maxillofac Surg. 1990;28(2):89-91. https://pubmed.ncbi.nlm.nih.gov/2337569/
  38. Porteder H, Rausch E, Kment G, Watzek G, Matejka M, Sinzinger H. Local prostaglandin E2 in patients with oral malignancies undergoing chemo- and radiotherapy. J Cranio-Maxillofacial Surg. 1988;16(C):371-374.
  39. Remy W, Sigl I, Leipold B. Prostaglandin E2 gel improvement of psoriatic lesions. Int J Dermatol. 1986;25(4):266-268. https://pubmed.ncbi.nlm.nih.gov/3458681/
  40. Pathak GN, Tan IJ, Bai G, Dhillon J, Rao BK. Vitiligo: From mechanisms of disease to treatable pathways. Ski Heal Dis. 2024;4(6). https://pubmed.ncbi.nlm.nih.gov/39624766/
  41. Marchioro HZ, Silva de Castro CC, Fava VM, Sakiyama PH, Dellatorre G, Miot HA. Update on the pathogenesis of vitiligo. An Bras Dermatol. 2022;97(4):478-490. https://pubmed.ncbi.nlm.nih.gov/35643735/
  42. Speeckaert R, Caelenberg E Van, Belpaire A, Speeckaert MM, Geel N van. Vitiligo: From Pathogenesis to Treatment. J Clin Med. 2024;13(17). https://pubmed.ncbi.nlm.nih.gov/39274437/
  43. Diotallevi F, Gioacchini H, De Simoni E, et al. Vitiligo, from Pathogenesis to Therapeutic Advances: State of the Art. Int J Mol Sci. 2023;24(5):4910. https://pmc.ncbi.nlm.nih.gov/articles/PMC10003418/
  44. Iwanowski T, Kołkowski K, Nowicki RJ, Sokołowska-Wojdyło M. Etiopathogenesis and Emerging Methods for Treatment of Vitiligo. Int J Mol Sci. 2023;24(11). https://pubmed.ncbi.nlm.nih.gov/37298700/
  45. Tomita Y, Iwamoto M, Masuda T, Tagami H. Stimulatory effect of prostaglandin E2 on the configuration of normal human melanocytes in vitro. J Invest Dermatol. 1987;89(3):299-301. https://pubmed.ncbi.nlm.nih.gov/3305717/
  46. Nordlund JJ, Collins CE, Rheins LA. Prostaglandin E2 and D2 but not MSH stimulate the proliferation of pigment cells in the pinnal epidermis of the DBA/2 mouse. J Invest Dermatol. 1986;86(4):433-437. https://pubmed.ncbi.nlm.nih.gov/3528310/
  47. Pourriyahi H, Hosseini NS, Nooshabadi MP, et al. Utility of prostaglandin analogues and phosphodiesterase inhibitors as promising last resorts for the treatment of vitiligo: A systematic review, from mechanisms of action to mono-, combination and comparative therapies. J Cosmet Dermatol. 2024;23(11). https://pubmed.ncbi.nlm.nih.gov/39158214/
  48. Kim JY, Shin JY, Kim MR, Hann SK, Oh SH. siRNA-mediated knock-down of COX-2 in melanocytes suppresses melanogenesis. Exp Dermatol. 2012;21(6):420-425. https://pubmed.ncbi.nlm.nih.gov/22506937/
  49. Neinaa YMEH, Mahmoud MAE, El Maghraby GM, Ibrahim ZAE. Efficacy of prostaglandin E2 versus prostaglandin F2 alpha assisted with narrowband-UVB in stable vitiligo. Arch Dermatol Res. 2023;315(9):2647. https://pmc.ncbi.nlm.nih.gov/articles/PMC10514142/
  50. Scott G, Leopardi S, Printup S, Malhi N, Seiberg M, LaPoint R. Proteinase-activated receptor-2 stimulates prostaglandin production in keratinocytes: analysis of prostaglandin receptors on human melanocytes and effects of PGE2 and PGF2alpha on melanocyte dendricity. J Invest Dermatol. 2004;122(5):1214-1224. https://pubmed.ncbi.nlm.nih.gov/15140225/
  51. Soontrapa K, Honda T, Sakata D, et al. Prostaglandin E2-prostoglandin E receptor subtype 4 (EP4) signaling mediates UV irradiation-induced systemic immunosuppression. Proc Natl Acad Sci U S A. 2011;108(16):6668-6673. https://pmc.ncbi.nlm.nih.gov/articles/PMC3081002/
  52. Fu C, Chen J, Lu J, et al. Roles of inflammation factors in melanogenesis (Review). Mol Med Rep. 2020;21(3):1421-1430. https://pubmed.ncbi.nlm.nih.gov/32016458/
  53. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatology Venereol. 2018;32(5):657-682. https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.14891
  54. Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15(4):457-465. https://pubmed.ncbi.nlm.nih.gov/26789102/
  55. Singh RK. Impact of Ultraviolet Light on Vitiligo. Adv Exp Med Biol. 2017;996:55-60. https://pubmed.ncbi.nlm.nih.gov/29124690/
  56. Parsad D, Pandhi R, Dogra S, Kumar B. Topical prostaglandin analog (PGE2) in vitiligo--a preliminary study. Int J Dermatol. 2002;41(12):942-945. https://pubmed.ncbi.nlm.nih.gov/12492997/
  57. Kapoor R, Phiske MM, Jerajani HR. Evaluation of safety and efficacy of topical prostaglandin E2 in treatment of vitiligo. Br J Dermatol. 2009;160(4):861-863. https://pubmed.ncbi.nlm.nih.gov/19014395/
  58. Anbar TS, El-Ammawi TS, Abdel-Rahman AT, Hanna MR. The effect of latanoprost on vitiligo: a preliminary comparative study. Int J Dermatol. 2015;54(5):587-593. https://pubmed.ncbi.nlm.nih.gov/25545321/
  59. Korobko I V., Lomonosov KM. A pilot comparative study of topical latanoprost and tacrolimus in combination with narrow-band ultraviolet B phototherapy and microneedling for the treatment of nonsegmental vitiligo. Dermatol Ther. 2016;29(6):437-441. https://pubmed.ncbi.nlm.nih.gov/27329330/
  60. Neinaa YMEH, Lotfy SS, Ghaly NR, Doghaim NN. A comparative study of combined microneedling and narrowband ultraviolet B phototherapy versus their combination with topical latanoprost in the treatment of vitiligo. Dermatol Ther. 2021;34(2). https://pubmed.ncbi.nlm.nih.gov/33497514/
  61. Fawzy M, Al-Mokadem S, Alshereef M, Elkholy B. Narrowband ultraviolet B phototherapy combined with intralesional injection of either latanoprost or platelet-rich plasma for stable nonsegmental vitiligo. Photodermatol Photoimmunol Photomed. 2024;40(1). https://pubmed.ncbi.nlm.nih.gov/37984828/
  62. Eldelee SA, Gheida SF, Sarhan NI, Ibrahim ZA, Elfar NN. Evaluation of the effect of combined intralesional injection of prostaglandin F2α with narrow band UVB phototherapy in treatment of resistant cases of vitiligo. J Dermatolog Treat. 2021;32(4):383-390. https://pubmed.ncbi.nlm.nih.gov/31437059/
  63. Kanokrungsee S, Khunkhet S, Rojhirunsakool S, Thadvibun K, Sahaspot T. Triple combination therapy of narrowband ultraviolet B, fractional carbon dioxide laser and topical bimatoprost 0.01% for non-segmental vitiligo on non-facial areas: A randomized half-body, double-blind, placebo-controlled, comparative study. Dermatol Ther. 2022;35(1). https://pubmed.ncbi.nlm.nih.gov/34750933/
  64. Omar SS, Elmulla KF, Aly RG, Elkaffas A, Ismail A. A triple combination of latanoprost, fractional CO2 laser, and platelet-rich plasma in localized vitiligo: A clinical and histopathologic study. Photodermatol Photoimmunol Photomed. 2024;40(1). https://pubmed.ncbi.nlm.nih.gov/38288773/
  65. Zaky MS, Atallah RB, El Abasy NTA, Elsaie ML. Comparative study between efficacy of Excimer light with topical Tacrolimus 0.1% versus excimer light with topical Bimatoprost 0.01% in treatment of facial Vitiligo. Arch Dermatol Res. 2024;316(7). https://pubmed.ncbi.nlm.nih.gov/38850408/
  66. Ghiasi M, Isazade A, Marhamati T, Lajevardi V, Shakoei S. The Efficacy of 308-nm Excimer Laser With TopicalBimatoprost 0.03% for Facial Vitiligo. J Cosmet Dermatol. 2025;24(2). https://pubmed.ncbi.nlm.nih.gov/39968721/

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Eco-Vector,


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 86501 от 11.12.2023 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80653 от 15.03.2021 г.